EN DE
Watch Shinhung for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Shinhung (004080) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Shinhung stock KRW 5,076, price KRW 14,550, that is 65.1% below the price, quality 53 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7004080008

S Shinhung logo Some data Nov 8, 2026

Shinhung

004080 · KO
Solid, but very expensive

Our calculation puts a fair price 65% below what the stock costs today.

Low debt
Ranks above peers (9/13)
Profit last quarter +107% vs. a year ago.
Quality 53/100
Thin margins · 5.1% net margin (TTM)
2.5% dividend yield · Watch coverage
Some data
Fair value 5,076 KRW · Strongly overvalued
Weak Growth (revenue 5y −2.5 %/yr in KRW)
Negative free cash flow
Narrow moat 36/100 · thin data
⚠ Small free float
Watch Shinhung for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

16,755 KRW 12,999 KRW Fair Value 5,076 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range 12,999 KRW – 16,755 KRW · fair‑value band 3,553 KRW – 6,599 KRW · the 14,550 KRW price screens above the 5,076 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Shinhung in your weekly email

Every Wednesday you see whether Shinhung is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shinhung Co., Ltd. manufactures, imports, and sells dental products and supplies in South Korea.

Show moreShow less

Its products include implant systems; dental units and chairs; dental alloys, such as composition tables, crowns, and porcelain under the Goldenian brand name; prefabricates SS crowns; taurus, insert, and mobile cabinets; compressors and mixers; dental needles; dental porcelain powder and laboratory products; and disposable needles, dental operatories, and autoclaves and X-ray equipment.

The company also offers loan services for dentists. Shinhung Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.

Stock analysis

Shinhung (004080) currently trades at 14,550 KRW, while our model-based Fair Value estimate is 5,076 KRW, 65% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 10,545 KRW per share, and 1 of the 14 models we run sit above the 14,550 KRW price.

Bear case: the Dividend Discount group reads lowest at 2,314 KRW, and 13 of the 14 models stay below the price. Data coverage for this calculation is medium.

Scenario range: 3,553 KRW (bear) to 6,599 KRW (bull), the price of 14,550 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Shinhung reported revenue of 103B KRW in FY2025 versus 127B KRW in FY2021, a compound −5.2%/yr. Reported net income was 2.8B KRW in FY2025, compounding −32.3%/yr from FY2021.

Key figures

Market cap 137B KRW (≈ $102M) Micro · P/E ratio 25.2 · P/S ratio 1.30 · EPS (TTM) 579.85 KRW · Dividend yield 2.5% · Net margin 5.1% · Return on equity 4.7% · Return on assets (EBIT) 6.8% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (low confidence).

What moves the price

The share trades about 1% below its 52-week high and 12% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −65%, 004080 screens richer than that median.

Fair Value models

Bear 3,553 KRW Fair Value 5,076 KRW Bull 6,599 KRW
Price 14,550 KRW · Downside -65.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (188.53 KRW per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income 7,873 KRW 8,015 KRW 8,343 KRW 76
EPV 2,888 KRW 3,264 KRW 3,574 KRW 74
ROIC Compounder 2,888 KRW 3,264 KRW 3,574 KRW 72
All 14 models by family
Earnings-Based
Graham-Dodd 2,077 KRW 2,539 KRW 2,856 KRW 67
EPV 2,888 KRW 3,264 KRW 3,574 KRW 74
Dividend Discount
Gordon GGM 2,058 KRW 2,210 KRW 2,435 KRW 69
DDM Multi-Stage 2,058 KRW 2,419 KRW 2,876 KRW 67
Multiples
P/E Multiple 5,040 KRW 6,721 KRW 8,401 KRW 63
P/S Multiple 3,895 KRW 5,193 KRW 6,492 KRW 58
P/B Multiple 10,904 KRW 14,538 KRW 18,173 KRW 55
EV/EBIT 8,819 KRW 12,080 KRW 15,342 KRW 66
EV/EBITDA 11,471 KRW 15,617 KRW 19,762 KRW 67
EV/Revenue 6,017 KRW 9,010 KRW 12,004 KRW 53
Asset-Based
NCAV (Graham) 1,919 KRW 2,908 KRW 3,635 KRW 54
Economic Profit
Residual Income 7,873 KRW 8,015 KRW 8,343 KRW 76
ROIC Compounder 2,888 KRW 3,264 KRW 3,574 KRW 72
Growth Earnings
Growth-Adj P/E 3,553 KRW 5,076 KRW 6,599 KRW 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 53/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 31
How much profit the company makes from its sales and capital
Quality Growth 35
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 80
Debt, balance sheet and risk of trouble
Investment 90
Does it invest with discipline instead of growing at any price?
Low Volatility 100
How calm the share price moves, does not count
Price momentum 45
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 65
Distance to the 52-week high, does not count
New shares 80
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 12/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+0.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.5%
Start year 2020 (pandemic). Over 10 years: −2.0% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.1%
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+20.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.8%
Dividend (yield on the price)2.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−25.5% vs 9.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 7%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 2.3%/yr over ~7Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

004080 screens overvalued: fair value 65% below the price. Compare with Abbott Laboratories, →

Compare Shinhung with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks

Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 53 · Above median
Fair Value upside −65.1% · Bottom 25%
Profitability
Return on equity (12 months) 4.7% · Above median
Return on assets 1.9% · Below median
Net margin (12 months) 5.1% · Below median
Operating margin (12 months) 13.9% · Above median
Growth and dividend
Revenue growth (quarter YoY) 7.1% · Below median
Dividend yield (12 months) 2.5% · Above median
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (12 months) 25.2× · Cheaper than median
P/B 1.19× · Cheaper than median
P/S (12 months) 1.30× · Cheapest 25%
EV/EBITDA 10.7× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)36 · sector 36
PAST (return on equity)19 · sector 17
HEALTH (low debt)99 · sector 98
DIVIDEND (yield)49 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shinhung: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Shinhung Fair Value". https://www.fairvalue-calculator.com/stock/004080

Frequently asked questions

Is Shinhung (004080) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 5,076 KRW versus a price of 14,550 KRW, about 65% lower (overvalued).
What is the fair value of 004080?
Our model-based fair value for Shinhung is 5,076 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 14,550 KRW.
What is the quality score of 004080?
Shinhung has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shinhung (004080)?
Our model-based price target is the fair value of 5,076 KRW (as of Nov 8, 2026) from 14 valuation models. Cautious scenario 3,553 KRW, optimistic scenario 6,599 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Shinhung stock forecast for 2026?
Our models put fair value at 5,076 KRW, about 65% lower versus a price of 14,550 KRW (overvalued). Cautious scenario 3,553 KRW, optimistic scenario 6,599 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Shinhung (004080)?
Shinhung reported trailing-twelve-month revenue of about 106B KRW (latest available figure, as of Nov 8, 2026).
Does Shinhung pay a dividend?
Shinhung currently shows a dividend yield of 2.47% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Shinhung (004080) and when is the ex-dividend date?
Shinhung pays a dividend of 360.00 KRW per share a year, a dividend yield of 2.5%. The last ex-dividend date was Jun 29, 2026. A dividend has been paid every year since at least 1996. The payout ratio is 62.1% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Shinhung (004080)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shinhung it is 5,076 KRW per share (as of Nov 8, 2026), against a price of 14,550 KRW. It is the blended result of 14 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Shinhung stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 004080 trades above its calculated fair value: price 14,550 KRW, fair value 5,076 KRW, a gap of about −65% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 004080?
No. The price is what the market pays today (14,550 KRW); the fair value is what the company's own numbers justify (5,076 KRW). For Shinhung the two are 9,474 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Shinhung worth?
The market values Shinhung at about 137B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 14,550 KRW; our models calculate a fair value of 5,076 KRW per share.
What do the bullish and bearish scenarios say about 004080?
Our models span a range for Shinhung: cautious scenario 3,553 KRW, base 5,076 KRW, optimistic 6,599 KRW per share (as of Nov 8, 2026, price 14,550 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 004080?
Shinhung trades at a price-to-earnings ratio of 25.2 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 5,076 KRW is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 29.0. Other multiples: P/B 1.2, P/S 1.3, EV/EBITDA 10.7.
How solid is the balance sheet of Shinhung (004080)?
Balance-sheet figures for Shinhung (as of Nov 8, 2026): return on equity 4.7%, debt of 0.02 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 004080 from its 52-week high?
Shinhung trades at 14,550 KRW, about 1% below its 52-week high of 14,700 KRW and 12% above the low of 13,027 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 5,076 KRW is for.
Which stocks are comparable to Shinhung?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shinhung stock attractive at the current price?
The data as of Nov 8, 2026: price 14,550 KRW, calculated fair value 5,076 KRW (−65%), Quality Score 53/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 004080 calculated?
We run Shinhung through 14 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 5,076 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Shinhung itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shinhung (004080)?
The closing price on Nov 6, 2026 was 14,550 KRW. Our model-based fair value is 5,076 KRW, about 65% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shinhung right now?
The price sits above even our optimistic bull case (6,599 KRW). The favourable scenario is already priced in. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (3,553 KRW to 6,599 KRW) leaves room in how you read the outcome.

Key figures of Shinhung

How large is the market capitalisation of Shinhung (004080)?
The market capitalisation of Shinhung is 137B KRW (≈ $102M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shinhung (004080)?
The price-to-sales ratio of Shinhung is 1.30 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shinhung (004080)?
Earnings per share at Shinhung are 579.85 KRW (price ÷ EPS = P/E 25.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shinhung (004080)?
The dividend yield of Shinhung is 2.5% (payout 62.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shinhung (004080)?
The net margin of Shinhung is 5.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shinhung (004080)?
The return on equity (ROE) of Shinhung is 4.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shinhung (004080)?
On an EBIT basis the return on assets of Shinhung is 6.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shinhung (004080)?
The operating margin of Shinhung is 13.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shinhung (004080)?
Revenue at Shinhung is growing +7.1% versus a year earlier (3y avg −4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shinhung (004080)?
Earnings per share at Shinhung are growing +107% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Shinhung (004080) generate?
The free cash flow of Shinhung is −1.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Shinhung (004080) carry?
The net debt of Shinhung is 8.9B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Shinhung in the live analysis

One click puts Shinhung on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.